Man loses gallbladder after unmonitored GLP-1 weight-loss drug use

The Waitlist That Drove a Patient Online

In May 2025, a 44-year-old man in England weighed 280 pounds and had spent three years struggling with back pain so severe that getting out of bed hurt. When he asked his general practitioner about GLP-1 medications—drugs like Mounjaro that mimic gut hormones to regulate blood sugar and suppress appetite—he was told the waiting list exceeded 12 months. Such delays had become increasingly common as demand for these medications surged, leaving NHS clinics stretched thin and patients searching for alternatives.

The man described his situation to reporters, explaining that he had sought medical help only to be told the wait would be more than a year. For someone whose daily life was limited by chronic pain, the prospect of such a delay felt insurmountable. With few options available, he turned to an online pharmacy, where he obtained a prescription for Mounjaro without direct medical oversight.

The man, a professional drummer and father of two, had tried multiple approaches to manage his weight. The appeal of a faster solution was not just about appearance but about regaining mobility, reducing pain, and maintaining his ability to care for his children. When the medication arrived, the effects were noticeable. Within two months, his back pain subsided. By the end of the year, he had lost 80 pounds, reaching 201 pounds. He later reflected on the changes, saying he felt healthier than he had in years.

However, the lack of medical supervision introduced risks that became apparent only later.

The Pain That Wouldn’t Go Away

In March 2026, nearly a year after starting the medication, he began experiencing a sharp, persistent pain in his abdomen. Initially, he assumed it was trapped gas, a recurring issue he had managed before. Over-the-counter remedies provided no relief, and the discomfort intensified until sitting or lying down became unbearable. He recalled trying various treatments without success, as the pain continued to worsen.

His partner found him doubled over on the floor, unable to speak clearly. An ambulance rushed him to the hospital, where tests revealed a grim diagnosis: gangrenous cholecystitis, a condition in which gallbladder tissue dies due to restricted blood flow. The infection had already spread to his stomach and lungs. Emergency surgery was necessary, and four days later, he returned home with an IV antibiotic drip after his gallbladder was removed.

The surgeons who treated him noted that his survival was not guaranteed. The man later described the experience, saying the severity of the situation became clear only in hindsight. He emphasized the gravity of his condition, explaining that the outcome could have been far worse if he had delayed seeking care. The experience left a lasting impression, particularly the thought of what might have happened to his family had the infection progressed unchecked.

Rapid Weight Loss and the Gallbladder’s Hidden Risk

GLP-1 medications like Mounjaro are not inherently dangerous when prescribed and monitored by a healthcare provider. They are approved for type 2 diabetes and obesity, with research demonstrating their effectiveness in improving blood sugar control and supporting weight loss. However, rapid weight loss—regardless of the method—carries inherent risks, and gallbladder complications are among the most serious.

When the body loses weight quickly, the liver releases excess cholesterol into bile, which can crystallize and form gallstones. If a stone obstructs the bile duct, it may lead to inflammation, infection, and, in severe cases, tissue death. The man’s experience reflects a well-documented medical phenomenon: patients who lose significant weight in short periods face an elevated risk of gallbladder disease. What made his case particularly concerning was the speed at which his condition deteriorated. Within days, his symptoms escalated from mild discomfort to a critical infection.

The manufacturer of Mounjaro, Eli Lilly, has emphasized that patient safety is a priority. However, safety protocols rely on medical supervision, including regular check-ups, blood tests, and dosage adjustments. When patients bypass these safeguards, the risks increase. The man’s experience serves as a reminder of what can happen when the pursuit of rapid results intersects with the realities of unmonitored treatment.

The Online Pharmacy Loophole

Online pharmacies have become a more accessible option for patients seeking prescription medications, particularly for those facing long waitlists or high costs. These platforms provide an alternative, but they also operate within a regulatory framework that varies in its enforcement. In the UK, online pharmacies must be registered with the General Pharmaceutical Council, though the level of oversight can differ. Some require consultations with healthcare professionals, while others may approve prescriptions based on self-reported questionnaires.

The man in this case obtained his medication through one such platform, believing it to be a legitimate and safe source. His experience is not unique. Online forums and discussion boards contain numerous accounts from patients who have used GLP-1 medications purchased through similar channels, with outcomes ranging from positive to concerning. The lack of transparency regarding sourcing, dosage, and potential interactions with other medications adds an element of uncertainty to these transactions.

Healthcare systems, already under strain, have struggled to meet rising demand. In the UK, the NHS has faced criticism over lengthy waitlists, which have led some patients to explore unregulated alternatives. The man’s story illustrates a broader challenge: when conventional treatment pathways are difficult to access, patients may turn to riskier options. His case underscores the potential consequences of such choices.

What Happens Now?

The man’s ordeal has left him with lasting physical and emotional effects. While he has recovered, the experience has stayed with him. He has since shared his story to caution others considering unsupervised use of GLP-1 medications. Reflecting on his decision, he acknowledged the appeal of a quick solution but emphasized the importance of weighing the risks.

His experience raises important questions about how these drugs are prescribed, monitored, and accessed. Will healthcare systems find ways to accommodate growing demand, or will patients continue to seek alternatives outside regulated channels? Will regulators strengthen oversight of online pharmacies, or will the market remain difficult to navigate for those in need of treatment?

For now, the answers remain uncertain. What is clear is that the pursuit of rapid weight loss carries risks that extend beyond immediate results. The man’s story serves as a cautionary example—not just about the potential dangers of a single medication, but about the broader implications of a healthcare system where patients may feel they have few viable options. The lesson is straightforward: when it comes to health, shortcuts can come with serious consequences.

For those considering GLP-1 medications, the message is equally clear: the risks of proceeding without professional guidance are significant and should not be overlooked.